In addition, a meta-analysis showed that, cabergoline single-agent therapy normalizes IGF-I levels in one third of patients with acromegaly, while in resistant acromegaly IGF-1 normalization is achieved in about half of patients when cabergoline is added to SSAs [93]. This evidence concerns the gene IGF1 and acromegaly.